Cellegy&#39;s investors find FDA&#39;s rejection painful
451724
Cellegy Pharmaceuticals Inc. (Nasdaq: CLGY) of South San Francisco saw its shares lose about half their value Monday after the US Food and Drug Administration rejected the company&#39;s nitroglycerine ointment for treating pain from chronic anal fissure.
708637
An enormous number of consumer complaints shows investors why this company is hurting.
50303
All of the human embryonic stem cells available to federally funded scientists under President Bush&#39;s three-year-old research policy share a previously unrecognized trait that fosters rejection
324740
A company scolded in Congress and  criticized by religious groups for an experiment involving  human embryonic stem cells clarified its work on Wednesday and  said it had demonstrated an acceptable alternative to producing  the controversial cells.
709830
Encysive gets set for a showdown with the FDA.
608577
EPIX Pharmaceuticals gets a qualified "yes" from the FDA, sending its stock tumbling.
403625
Be very wary of biotech IPOs from companies lacking drugs.
730876
GlaxoSmithKlineâs effort to focus Avandiaâs marketing on African-Americans could backfire as questions arise.
305997
The Securities and Exchange Commission is scrutinizing biotechnology companies as part of a wider effort to ensure that companies don&#39;t mislead investors
145474
Looking over all the biotech stock stories I covered in 2004, I&#39;m pleased to report that I was right more than wrong. My &quot;win&quot; column does veer in the bearish direction, which is not ideal (I&#39;d prefer more
414602
Stock falls on news treatment failed a mid-stage trial, company will cease developing drug. NEW YORK  - AtheroGenics Inc.
114185
Shares drop as U.S. regulators say they want more info before approving caner medication Bonefos.
499096
NEW YORK, December 27  - Analyst Bal Bagwat of JM Dutton downgrades Cellegy Pharmaceuticals Incorporated (ticker: CLGY) from &quot;speculative strong buy&quot; to &quot;neutral,&quot; while reducing his estimates for the company.
124030
Almost one-fifth of the Food and Drug Administration scientists surveyed two years ago as part of an official review said they had been pressured to recommend approval of a new drug despite
769110
I won't quibble with the investment performance celebrated (&quot;A quiet top gun, Sept. 21), but it's telling -- and frankly sad -- that the way Ed Owens &quot;beat the market&quot; for 20 years was with a fund &quot;dominated by investments in big pharmaceutical companies.&quot;
640534
Its failure to acquiesce to the FDA's request means the competition is going forward as this drugmaker's product stays stagnant.
372192
A clinical trial of Zetia, a widely used cholesterol drug, has raised questions about its effectiveness and the behavior of pharmaceutical companies that conducted the study.